Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England, AI Startup Collaborate on Immunotherapy

NEW YORK (GenomeWeb) – Genomics England said today that it has enlisted a startup maker of artificial intelligence in a long-term partnership meant to increase patient access to immunotherapies, monitor treatment effectiveness, and identify resistance to these advanced cancer drugs.

As part of the partnership, Cambridge Cancer Genomics — known as CCG.ai — is joining the Discovery Forum, a Genomics England-led collaboration platform for genomics researchers in the UK. CCG.ai also will contribute its liquid biopsy technology and a sequencing panel that measures tumor mutational burden to assess treatment resistance to immunotherapy drugs.

"Through genomic analysis of longitudinal liquid biopsy samples collected on a bi-weekly basis, we are able to detect the signals of resistance and relapse much earlier than standard of care. In this project, we hope to extend this technology to a new class of breakthrough cancer medicines," CCG.ai Chief Scientific Officer Nirmesh Patel said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.